Most importantly, inhibition of PDE4 by Rofi could rescue the symptoms of DSS-induced colitis in vivo, and DIP administration could alleviate clinical symptoms of IBD in a clinical pilot study. The gene discussed is PDE4A; the disease is inflammatory bowel disease.